Enliven Therapeutics (ELVN) News Today $16.62 -0.57 (-3.32%) As of 02:55 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Fmr LLCFmr LLC raised its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,495,871 shares of the company's stock after acquiring an additional 199,692 shApril 15 at 3:58 AM | marketbeat.comFederated Hermes Inc. Takes $2.65 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Federated Hermes Inc. acquired a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 117,552 shares of the company's stock, valuApril 15 at 3:57 AM | marketbeat.comVanguard Group Inc. Purchases 55,283 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Vanguard Group Inc. raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,975,655 shares of the coApril 14 at 3:21 AM | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week Low - Time to Sell?Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year Low - Should You Sell?April 11, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Shares Down 9.1% - Here's What HappenedEnliven Therapeutics (NASDAQ:ELVN) Shares Down 9.1% - What's Next?April 10, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 SharesApril 10, 2025 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increase - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume - Should You Buy?April 4, 2025 | marketbeat.comEnliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual MeetingApril 2, 2025 | prnewswire.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.9% Following Insider SellingEnliven Therapeutics (NASDAQ:ELVN) Shares Down 4.9% Following Insider SellingApril 2, 2025 | marketbeat.comPictet Asset Management Holding SA Has $21.88 Million Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Pictet Asset Management Holding SA boosted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 16.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 972,293 shares of the company's stock afterApril 2, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $21.33, for a total value of $69,322.50. Following the sale, the chief financial officer now directly owns 23,000 shares of the company's stock, valued at $490,590. This represents a 12.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.April 1, 2025 | marketbeat.comBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockApril 1, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,500.00 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $22.50, for a total value of $22,500.00. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares in the company, valued at approximately $517,500. The trade was a 4.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 27, 2025 | marketbeat.comBenjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMarch 27, 2025 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) Trading Down 7.8% - Here's What HappenedEnliven Therapeutics (NASDAQ:ELVN) Trading Down 7.8% - Should You Sell?March 26, 2025 | marketbeat.com16,322 Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Purchased by Intech Investment Management LLCIntech Investment Management LLC purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,322 shares of the company's stock, valued at approximaMarch 26, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 12,500 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $20.61, for a total value of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares of the company's stock, valued at approximately $20,665,399.68. This represents a 1.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.March 22, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock PriceHC Wainwright upped their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research note on Friday.March 22, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $257,625.00 in StockMarch 22, 2025 | insidertrades.comSamuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00. Following the completion of the transaction, the chief executive officer now owns 990,392 shares in the company, valued at $20,629,865.36. The trade was a 1.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.March 20, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $260,375.00 in StockMarch 20, 2025 | insidertrades.comLifesci Capital Issues Optimistic Forecast for ELVN EarningsEnliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Equities researchers at Lifesci Capital raised their FY2025 earnings estimates for shares of Enliven Therapeutics in a research report issued to clients and investors on Monday, March 17th. Lifesci Capital analyst S. Slutsky now anticipatesMarch 20, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPSEnliven Therapeutics (NASDAQ:ELVN - Get Free Report) announced its earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.07.March 14, 2025 | marketbeat.comEnliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateMarch 14, 2025 | finanznachrichten.deTD Cowen Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)March 14, 2025 | markets.businessinsider.comEnliven Therapeutics Reports 2024 Financial ResultsMarch 14, 2025 | tipranks.comEnliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateMarch 13, 2025 | prnewswire.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $142,940.48 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $21.44, for a total value of $142,940.48. Following the completion of the transaction, the chief operating officer now directly owns 323,310 shares in the company, valued at $6,931,766.40. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.March 12, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Up 4.5% - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Trading 4.5% Higher - Here's WhyMarch 7, 2025 | marketbeat.comEnliven Therapeutics (ELVN) Projected to Post Quarterly Earnings on ThursdayEnliven Therapeutics (NASDAQ:ELVN) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $66,332.50 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50. Following the transaction, the chief financial officer now directly owns 13,000 shares in the company, valued at approximately $265,330. This represents a 20.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.March 4, 2025 | marketbeat.comEnliven Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | prnewswire.comEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Here's What HappenedEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Here's WhyFebruary 13, 2025 | marketbeat.comEnliven Therapeutics COO Anish Patel sells $146,205 in stockFebruary 11, 2025 | msn.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in StockFebruary 11, 2025 | insidertrades.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 6,667 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the business's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $21.93, for a total transaction of $146,207.31. Following the completion of the transaction, the chief operating officer now owns 329,977 shares in the company, valued at approximately $7,236,395.61. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.February 10, 2025 | marketbeat.comEnliven Therapeutics CFO sells $22,524 in stockFebruary 8, 2025 | msn.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,520.00 in StockFebruary 8, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 SharesEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $22.52, for a total transaction of $22,520.00. Following the completion of the transaction, the chief financial officer now owns 13,000 shares in the company, valued at $292,760. This trade represents a 7.14 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.February 7, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $70,167.50 in StockJanuary 30, 2025 | insidertrades.comEnliven Therapeutics CFO sells $70,177 in stockJanuary 29, 2025 | msn.comEnliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume - Here's WhyEnliven Therapeutics (NASDAQ:ELVN) Sees Strong Trading Volume - Time to Buy?January 24, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading 11.3% Higher - Here's WhyEnliven Therapeutics (NASDAQ:ELVN) Trading 11.3% Higher - Still a Buy?January 15, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increase - Here's WhyJanuary 14, 2025 | marketbeat.comBarclays PLC Acquires 42,012 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Barclays PLC lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 295.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,217 shares of the company's stock after pJanuary 13, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 21,700 Shares of StockJanuary 11, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $524,706.00 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 21,700 shares of the company's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $24.18, for a total transaction of $524,706.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.January 10, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Shares Down 9.8% - Here's WhyEnliven Therapeutics (NASDAQ:ELVN) Stock Price Down 9.8% - Time to Sell?January 10, 2025 | marketbeat.comEnliven Therapeutics: Still Too Early To Pay This MuchJanuary 7, 2025 | seekingalpha.comEnliven's Early Data Stands Out From PeersJanuary 7, 2025 | seekingalpha.com Remove Ads Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address ELVN Media Mentions By Week ELVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼0.740.80▲Average Medical News Sentiment ELVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼83▲ELVN Articles Average Week Remove Ads Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rhythm Pharmaceuticals News Today PTC Therapeutics News Today Organon & Co. News Today Zai Lab News Today Arcellx News Today Avidity Biosciences News Today Ultragenyx Pharmaceutical News Today Akero Therapeutics News Today MorphoSys News Today SpringWorks Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELVN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELVN Stock Free ELVN Stock Alerts